PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26047595-9 2015 Staurosporine, JNK inhibitor SP600125 and ERK inhibitor PD98059 significantly decreased DAX-1 expression in TNF-alpha-treated Leydig cells when compared to their respective controls. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 56-63 tumor necrosis factor Rattus norvegicus 108-117 28662519-8 2017 Similarly to PYC, NF-kappaB inhibitor PDTC and ERK1/2 inhibitor PD098059 dramatically inhibited OGD/R-induced NF-kappaB activation, ERK1/2 phosphorylation, and ROS production, as well as TNF-alpha secretion. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 64-72 tumor necrosis factor Rattus norvegicus 187-196 27784654-8 2016 Furthermore, CALCB increases ERK1/2 phosphorylation in a time-dependent manner in RUASM, and the protective effect of CALCB on TNFalpha-induced inhibition of CALCRL/RAMP1 associations was significantly blocked in presence of ERK inhibitor (PD98059). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 240-247 tumor necrosis factor Rattus norvegicus 127-135 26075533-9 2015 Treatment with ERK1/2 inhibitors (PD98059 and U0126) abolished the antagonistic effect of TGF-beta1 on TNF-alpha mediated catabolic responses. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 34-41 tumor necrosis factor Rattus norvegicus 103-112 27382351-9 2016 NF-kappaB inhibitor BAY11-7082 and ERK inhibitor PD98059 inhibited TNF-alpha-induced LOX-1 expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 49-56 tumor necrosis factor Rattus norvegicus 67-76 26505752-8 2016 The TNF-alpha promoter was suppressed completely in the presence of the ERK inhibitor PD98059 and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB202190, but not in the presence of the JNK inhibitor SP600125. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 86-93 tumor necrosis factor Rattus norvegicus 4-13 24161765-7 2013 Pre-treatment with NF-kappaB inhibitor PDTC, ERK inhibitor PD98059 or p38 MAPK inhibitor SB203580 at 30 min before TNF-alpha microinjected into the RN completely prevented TNF-alpha-evoked mechanical allodynia. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 59-66 tumor necrosis factor Rattus norvegicus 172-181 25338292-13 2015 IPC2 x 5 min significantly downregulates the expressions of NF-kappaB p65 and COX-2 and attenuates the release of TNF-alpha; all of which were abolished by LY294002 or (and) PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 174-181 tumor necrosis factor Rattus norvegicus 114-123 24802761-7 2014 PD98059 or NF-kappaB signal pathway selective inhibitor Bay 11-7082 effectively blocked TNF-alpha-induced expression of MMP-2 in rat MCs, as determined by gene and protein expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 tumor necrosis factor Rattus norvegicus 88-97 24802761-9 2014 Furthermore, TNF-alpha could induce the cell migration of rat MCs, whereas ERK signal pathway specific inhibitor PD98059 compromised the cell migration triggered by TNF-alpha. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 113-120 tumor necrosis factor Rattus norvegicus 165-174 24161765-9 2013 Post-treatment with PDTC, PD98059 or SP600125 (but not SB203580) at 4h after TNF-alpha microinjected into the RN significantly reversed TNF-alpha-evoked mechanical allodynia. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 26-33 tumor necrosis factor Rattus norvegicus 77-86 24161765-9 2013 Post-treatment with PDTC, PD98059 or SP600125 (but not SB203580) at 4h after TNF-alpha microinjected into the RN significantly reversed TNF-alpha-evoked mechanical allodynia. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 26-33 tumor necrosis factor Rattus norvegicus 136-145 23645013-9 2013 The LPS-induced overexpression of MCP-1 and TNF-alpha, and NO production were attenuated by pretreatment with the ERK inhibitor PD98059, the p38 MAPK inhibitor SB203580, the NF-kappaB inhibitor PDTC or anti-TLR4 antibody, but not with the JNK inhibitor SP600125. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 128-135 tumor necrosis factor Rattus norvegicus 44-53 22538404-10 2012 PD98059, a mitogen extracellular kinase 1/2 inhibitor, and curcumin, an Egr1 inhibitor, blocked the arachidonic acid-mediated upregulation of TNFalpha in Kupffer cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 tumor necrosis factor Rattus norvegicus 142-150 22528462-10 2012 However, they decreased markedly after rat TG pretreatment with PD98059 (ERK1/2 inhibitor), SB203580 (P38 inhibitor), or SP600125 (JNK inhibitor) compared with rat TG co-culture with TNF-alpha or IL-1beta. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 64-71 tumor necrosis factor Rattus norvegicus 183-192 19100731-4 2009 TNF-alpha-induced hepatocyte DNA synthesis and proliferation were blocked by AG1478 (10(-7) M), PD98059 (10(-6) M), LY 294002 (10(-7) M), and rapamycin (100 ng/ml). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 96-103 tumor necrosis factor Rattus norvegicus 0-9 20175209-9 2010 We also found that thrombin-induced production of tumor necrosis factor (TNF)-alpha was inhibited by PD98059, SB203580, and SP600125. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 101-108 tumor necrosis factor Rattus norvegicus 50-83 21371423-7 2011 MEK1 inhibitor PD98059 competed partially but significantly TNF-alpha-mediated downregulation of megalin mRNA expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 15-22 tumor necrosis factor Rattus norvegicus 60-69 21481306-4 2011 While application of ERK antagonist (PD98059) in rat AM and the expression of TNF-alpha was observed by Western blot. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 37-44 tumor necrosis factor Rattus norvegicus 78-87 21481306-7 2011 compared with LPS stimulation group, we found that ERK inhibitor (PD98059 30 mol/L), Gentiana veitchiorum particles intervention and Gentiana veitchiorum particles+PD98059 groups" TNF-alpha expression were significantly reduced in rat AM. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 66-73 tumor necrosis factor Rattus norvegicus 180-189 21481306-7 2011 compared with LPS stimulation group, we found that ERK inhibitor (PD98059 30 mol/L), Gentiana veitchiorum particles intervention and Gentiana veitchiorum particles+PD98059 groups" TNF-alpha expression were significantly reduced in rat AM. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 164-171 tumor necrosis factor Rattus norvegicus 180-189 20367970-11 2010 To compare with CME group, treatment of specific ERK1/2 inhibitor PD98059 blocked the activation of ERK1/2 (0.48 +/- 0.11 vs 0.92 +/- 0.10, P < 0.05), decreased inflammatory cells (401 +/- 12 vs 455 +/- 16, P < 0.05), decreased expression of TNF-alpha mRNA (0.42 +/- 0.06 vs 0.94 +/- 0.04, P < 0.05) and suppressed activity of NF-kappaB (105 +/- 14 vs 541 +/- 25, P < 0.05). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 66-73 tumor necrosis factor Rattus norvegicus 248-257 19181934-11 2009 Inhibition of ERK 1/2 MAPK with PD98059 attenuated the protective role of IL-10 against TNF-alpha-induced activation of IKK and NF kappaB as well as cardiomyocyte apoptosis. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 32-39 tumor necrosis factor Rattus norvegicus 88-97 16946004-6 2006 The mandatory phosphorylation of cAMP-responsive element binding was also observed in response to TNFalpha, SMase, or C6-cer and shown to be prevented by the p44/42 MAPK-specific inhibitor PD098059 but no other kinase blockers. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 189-197 tumor necrosis factor Rattus norvegicus 98-106 15641147-21 2005 However, TNF-alpha significantly decreased after pretreatment with glycine, PD98059 and SB212850. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 76-83 tumor necrosis factor Rattus norvegicus 9-18 15365619-9 2004 Pretreatment with PD98059 or PD169316, which inhibit p42/p44MAPK and p38MAPK respectively, restored insulin signalling and insulin-induced glucose uptake in the presence of TNF-alpha. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 18-25 tumor necrosis factor Rattus norvegicus 173-182 12485415-7 2003 CRH effects on TNF-alpha release were also inhibited by specific inhibitors of MEK, the upstream kinase of the extracellular signal-regulated protein kinase (ERK) (PD98059) or p38 mitogen-activated protein kinase (SB203580), but not by H89. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 164-171 tumor necrosis factor Rattus norvegicus 15-24 14764603-5 2004 However, in the presence of PD98059 or SP600125, inhibitors of p42/p44 MAPK or JNK, respectively, insulin resistance by TNF-alpha was still produced. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 28-35 tumor necrosis factor Rattus norvegicus 120-129 14871416-6 2004 RESULTS: PKC activation, TNFalpha, and 20 mmol/L glucose decreased PPARgamma1 at both protein and mRNA levels, which was inhibited by PD98059, a specific inhibitor of mitogen-activated protein kinase (MAPK). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 134-141 tumor necrosis factor Rattus norvegicus 25-33 12934647-4 2003 The inhibition of the ERK pathway, with a selective inhibitor, PD098059, blocked the expressions of IL-1beta and TNF-alpha-induced COX-2 and PGE2 release. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 63-71 tumor necrosis factor Rattus norvegicus 113-122 12608646-6 2003 The selective MAPK/Erk-1 inhibitor, PD98059 (10(-5) M) and the specific p38 inhibitor SB203580 (10(-5) M) significantly decreased LPS-induced TNF-alpha production in the cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 36-43 tumor necrosis factor Rattus norvegicus 142-151 15196247-6 2004 PD98059, an inhibitor of MAPK kinase (MEK), a component of the p44/42 MAPK pathway, partially inhibited Ag-induced expression of mRNA for all three cytokines while cyclosporin A inhibited Ag-induced IL-4 and IL-6 mRNA more readily than TNF-alpha mRNA. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 tumor necrosis factor Rattus norvegicus 236-245 14978197-5 2004 PD98059 abolished TNF-alpha-activated p42/44 MAPK phosphorylation and c-Fos up-regulation, whereas SP600125 inhibited TNF-alpha-activated JNK and c-Jun phosphorylation. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 tumor necrosis factor Rattus norvegicus 18-27 12028827-5 2002 Inhibition of ERK1/2 activation by the MEK inhibitor PD98059 abrogated nitric oxide and tumor necrosis factor-alpha (TNF-alpha) production in primary rat alveolar macrophages, but the p38 inhibitor SB203580 had no effect on the production of these two inflammatory mediators. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 53-60 tumor necrosis factor Rattus norvegicus 88-115 12445823-6 2002 Likewise, SB203580, which abolishes p38 activation, and PD098059, which abrogates ERK1/2 and NF-kappaB activation, diminish TNF-alpha generation. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 56-64 tumor necrosis factor Rattus norvegicus 124-133 12383959-7 2002 Addition of the kinase inhibitor, i.e. PD98059 (specific for the ERK pathway), inhibits and, in combination with the p38 MAPK inhibitor, SB203580, drastically suppresses AdV-induced expression of iNOS and TNFalpha. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 39-46 tumor necrosis factor Rattus norvegicus 205-213 12028827-5 2002 Inhibition of ERK1/2 activation by the MEK inhibitor PD98059 abrogated nitric oxide and tumor necrosis factor-alpha (TNF-alpha) production in primary rat alveolar macrophages, but the p38 inhibitor SB203580 had no effect on the production of these two inflammatory mediators. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 53-60 tumor necrosis factor Rattus norvegicus 117-126 11277995-3 2001 MEK inhibition with PD98059 abolished the inhibitory effect of TNF-alpha on UCP-1, but not on adipogenic genes. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 20-27 tumor necrosis factor Rattus norvegicus 63-72 11997699-5 2002 IL-10 release was suppressed by an inhibitor of p38 MAPK, SB203580 but not by an inhibitor of ERK pathway, PD98059, whereas both SB203580 and PD98059 inhibited TNF-alpha release. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 142-149 tumor necrosis factor Rattus norvegicus 160-169 11689211-11 2001 Induction of these transcription factors was mediated via ERK 1/2 activation, since the ERK 1/2-pathway inhibitor PD98059 (10-30 microM) significantly inhibited their TNFalpha-induced expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 114-121 tumor necrosis factor Rattus norvegicus 167-175 11131279-5 2000 Nitrite/nitrate (NOx) production stimulated by interleukin (IL)-1beta or tumor necrosis factor (TNF)-alpha in VSMCs was markedly suppressed by inhibiting MAP kinase by pretreatment with a p42/p44 MAP kinase kinase (MAPKK)-1 inhibitor (PD98059) or by transfecting the dominant-interfering form of the nonphosphorylated MAPKK-1 expressing construct (MAPKK S222A). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 235-242 tumor necrosis factor Rattus norvegicus 73-106 10936177-7 2000 ATP-induced TNF-alpha release was inhibited by PD 098059, an inhibitor of extracellular signal-regulated protein kinase (ERK) kinase 1 (MEK1), which activates ERK, and also by SB 203580, an inhibitor of p38 mitogen-activated protein kinase. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 47-56 tumor necrosis factor Rattus norvegicus 12-21 11069065-4 2000 By the use of the MEK inhibitor PD098059 we demonstrate that the MAPK pathway participates in the CD94-dependent TNF-alpha production and cytotoxicity. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 32-40 tumor necrosis factor Rattus norvegicus 113-122 9931102-6 1999 We found that TNF-alpha-directed migration was substantially inhibited by PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 74-81 tumor necrosis factor Rattus norvegicus 14-23 9931102-9 1999 PD98059 also blocked TNF-alpha-stimulated MAPK activation in a concentration-dependent manner, which is consistent with its inhibition of TNF-alpha-directed migration. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 tumor necrosis factor Rattus norvegicus 21-30 9931102-9 1999 PD98059 also blocked TNF-alpha-stimulated MAPK activation in a concentration-dependent manner, which is consistent with its inhibition of TNF-alpha-directed migration. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 tumor necrosis factor Rattus norvegicus 138-147 9579682-4 1998 Furthermore, co-treatment of SB203580 and PD098059 additively reduced NO and TNF-alpha release. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 42-50 tumor necrosis factor Rattus norvegicus 77-86 9439626-7 1998 Selective inhibition of MAPK activation by PD98059 resulted in a dose dependent inhibition of TNF-alpha or EGF-induced IEC-6 cell growth. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 43-50 tumor necrosis factor Rattus norvegicus 94-103 35465093-8 2022 However, intrarubral pretreatment with ERK inhibitor PD98059 only restrained the increase in spinal TNF-alpha and enhanced the expression of spinal IL-10. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 53-60 tumor necrosis factor Rattus norvegicus 100-109 10880840-8 2000 The PD098059 inhibitor decreased both IFN-gamma and TNF-alpha production and together with TGF-beta1, it totally blocked IFN-gamma, TNF-alpha and IL-10 production. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 4-12 tumor necrosis factor Rattus norvegicus 52-61 10880840-8 2000 The PD098059 inhibitor decreased both IFN-gamma and TNF-alpha production and together with TGF-beta1, it totally blocked IFN-gamma, TNF-alpha and IL-10 production. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 4-12 tumor necrosis factor Rattus norvegicus 132-141 10516205-5 1999 TNF-alpha enhancement of IL-1beta-induced NO(-)(2) production was blocked by PD-98059, a selective mitogen-activated protein (MAP) kinase kinase inhibitor, but not calphostin C (Cal C), a protein kinase C inhibitor. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 77-85 tumor necrosis factor Rattus norvegicus 0-9 10516205-7 1999 PD-98059, but not Cal C, inhibited both TNF-alpha-enhanced MAP kinase and NF-kappaB activities. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-8 tumor necrosis factor Rattus norvegicus 40-49 32380573-5 2020 Administration of either the JAK2 antagonist AG490 or the ERK antagonist PD98059 to the RN of rats with SNI remarkably increased the paw withdrawal threshold (PWT) and inhibited the up-regulations of local TNF-alpha and IL-1beta. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 73-80 tumor necrosis factor Rattus norvegicus 206-215